2026-10-19T00:37:42Zhttps://ebyu-rdlopen.rawdatalibrary.net/oai/request

oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/131752026-10-18T21:13:25Zopenairedrivercom_ebyu_10000col_ebyu_10001

Bilirubin levels as an independent predictor of myocarditis in patients with COVID-19Cosgun, Muharrem SaidBilirubinCOVID-19MicrothrombiMyocarditisantibiotic agentantivirus agentC reactive proteincorticosteroidD dimerheme oxygenase 1hydroxychloroquinetroponinadultArticlebilirubin blood levelclinical trialconfidence intervalcontrolled studycoronavirus disease 2019electrocardiographyenzyme activityfemalehumanKolmogorov Smirnov testmajor clinical studymalemiddle agedmultivariate analysismultivariate logistic regression analysisreverse transcription polymerase chain reactionBackground: Myocardial damage worsens the clinical course and prognosis of coronavirus disease 2019 (COVID-19) patients. High total bilirubin levels have been associated with a poor prognosis in COVID-19. This study aimed to investigate the predictive value of the total bilirubin level, a marker of heme oxygenase-1 enzyme activity, in determining myocarditis in patients with COVID-19. Results: A total of 190 patients diagnosed with COVID-19 were enrolled in the study. The patients were divided into two groups based on their troponin positivity. The study group (n = 95) consisted of patients with high troponin, and the control group (n = 95) consisted of patients without high troponin levels. The D-dimer (727 [572–995] vs. 591 [440–790], p = 0.001), C-reactive protein (CRP) (30.0 [10–48] vs. 10.3 [5.8–15.9], p < 0.001), and total bilirubin (9.5 [8.2–12.1] vs. 7.0 [5.3–8.0], p < 0.001) levels were significantly higher in the study group. In multivariate analysis, CRP (odds ratio [OR]: 1.103; 95% confidence interval [CI]: 1.060–1.148; p < 0.001) and total bilirubin (OR: 1.612; 95% CI: 1.330–1.954; p < 0.001) levels were independent predictors of myocarditis in COVID-19. Conclusions: Total bilirubin levels can be used as an early predictor of myocarditis in COVID-19 and can contribute to therapy management. © 2021, The Author(s).Springer Science and Business Media Deutschland GmbH2021Articlehttps://rdlopen.rawdatalibrary.net/r/ebyu/13175https://doi.org/10.1186/s43044-021-00234-w1110-2608enEgyptian Heart Journalinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/13175